<- Go Home
Neurogene Inc.
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Market Cap
$713.8M
Volume
183.0K
Cash and Equivalents
$112.5M
EBITDA
-$118.0M
Tax Rate Collected
N/A
Tax Rate Ratio
N/A
Gross Profit
-$88.4M
Profit Margin
N/A
52 Week High
$43.66
52 Week Low
$15.93
Dividend
N/A
Price / Book Value
2.60
Price / Earnings
-7.07
Price / Tangible Book Value
2.60
Enterprise Value
$496.8M
Enterprise Value / EBITDA
-4.31
Operating Income
-$121.2M
Return on Equity
45.32%
Return on Assets
-27.97
Cash and Short Term Investments
$225.4M
Debt
$8.3M
Equity
$217.1M
Revenue
N/A
Unlevered FCF
-$48.1M
Sector
Biotechnology
Category
N/A